Abstracts of 20th World CongressWorld Society of Cardio-Thoracic Surgeons - October 2010

DOI:

https://doi.org/10.1532/hsf.504

References

Rihal CS, Raco DL, Gersh BJ, Yusuf S. Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. Circulation 2003;108:2439-45.nHannan EL, Racz MJ, Wallford G, et al. Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 2005;352:2174-83.nThe SoS Investigators. Coronary artery bypass surgery versus percutaneous coronary intervention with stent implantation in patients with multivessel coronary artery disease (the Stent or Surgery Trial): a randomized, controlled trial. Lancet 2002; 360:965-70.nJones RH, Kesler K, Phillips HR III, et al. Long-term survival benefits of coronary artery bypass grafting and percutaneous transluminal angioplasty inpatients with coronary artery disease. J Thorac Cardiovasc Surg 1996;111:1013-25.nCutlip DE, Chhabra AG, Baim DS, et al. Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation 2004;110:1226-30.nBARI Trial Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol 2000;35:1122-9.nDetre KM, Guo P, Holubkov R, et al. Coronary revascularization in diabetic patients: a comparison of the randomized and observational components of the Bypass Angioplasty Revascularization Investigation (BARI). Circulation 1999;99:633-40.nGersh BJ, Frye RL. Methods of coronary revascularization - things may not be as they seem. N Engl J Med 2005;3.nIung B, et al. A prospective survey of patients with valvular heart disease in Europe: The Euro Heart Survey on Valvular Heart Disease. Eur Heart J. 2003. 24(13):1231-43.nSupino, PG, et al. The epidemiology of valvular heart disease: a growing public health problem. Heart Fail Clin. 2006. 2(4):379-93.nRoss Jr J, Braunwald E. Aortic stenosis. Circulation. 1968. 38(1 Suppl):61-7.nRosenhek, R, et al. Natural history of very severe aortic stenosis. Circulation. 121(1):151-6.nBonow RO, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008. 118(15):e523-661.nVahanian A, et al. Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J. 2007. 28(2):230-68.nIung B, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005. 26(24):2714-20.nSerruys PW. Keynote address-EuroPCR 2008, Barcelona, May 14th, 2008. Transcatheter aortic valve implantation: state of the art. EuroIntervention. 2009. 4(5):558-65.nCribier A, et al. Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis: first human case description. Circulation. 2002. 106(24):3006-8.nWebb JG, et al. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. Circulation. 2007. 116(7):755-63.nGrube E, et al. Percutaneous implantation of the CoreValve self-expanding valve prosthesis in high-risk patients with aortic valve disease: the Siegburg first-in-man study. Circulation. 2006. 114(15):1616-24.nPiazza N, et al. Procedural and 30-day outcomes following transcatheter aortic valve implantation using the third generation (18 Fr) corevalve revalving system: results from the multicentre, expanded evaluation registry 1-year following CE mark approval. EuroIntervention. 2008. 4(2):242-9.nBleiziffer S, et al. Survival after transapical and transfemoral aortic valve implantation: talking about two different patient populations. J Thorac Cardiovasc Surg. 2009. 138(5):1073-80.nWebb JG, et al. Transcatheter aortic valve implantation: impact on clinical and valve-related outcomes. Circulation. 2009. 119(23):3009-16.nThomas M, et al. Thirty-Day Results of the SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) Registry. A European Registry of Transcatheter Aortic Valve Implantation Using the Edwards SAPIEN Valve. Circulation.nGerckens U, et al. Procedural and mid-term results in patients with aortic stenosis treated with implantation of 2 (in-series) CoreValve prostheses in 1 procedure. JACC Cardiovasc Interv. 3(2):244-50.nBrown JM, et al. Isolated aortic valve replacement in North America comprising 108,687 patients in 10 years: changes in risks, valve types, and outcomes in the Society of Thoracic Surgeons National Database. J Thorac Cardiovasc Surg. 2009. 137(1):82-90.nHalkos ME, et al. Aortic valve replacement for aortic stenosis in patients with left ventricular dysfunction. Ann Thorac Surg. 2009. 88(3):746-51.nMaslow A, et al. Aortic valve replacement with or without coronary artery bypass graft surgery: the risk of surgery in patients > or =80 years old. J Cardiothorac Vasc Anesth. 24(1):18-24.nChang AS, et al. Cardiac surgery after mediastinal radiation: extent of exposure influences outcome. J Thorac Cardiovasc Surg. 2007. 133(2):404-13.nWalther T, et al. Transapical aortic valve implantation in 100 consecutive patients: comparison to propensity-matched conventional aortic valve replacement. Eur Heart J. 2010. 31(11):1398-403.nPiazza N, et al. A comparison of patient characteristics and 30-day mortality outcomes after transcatheter aortic valve implantation and surgical aortic valve replacement for the treatment of aortic stenosis: a two-centre study. EuroIntervention. 2009. 5(5):580-8.nMasson JB, et al. Transcatheter aortic valve implantation: review of the nature, management, and avoidance of procedural complications. JACC Cardiovasc Interv. 2009. 2(9):811-20.nPiazza N, et al. Clinical endpoints in transcatheter aortic valve implantation: a call to ARC for standardised definitions. EuroIntervention. 2009. 5(1):29-31.nThomas M, Wendler O. Transcatheter aortic valve implantation (TAVI): how to interpret the data and what data is required? EuroIntervention. 2009. 5(1):25-7.nVan Brabandt H, Neyt M. Safety of percutaneous aortic valve insertion. A systematic review. BMC Cardiovasc Disord. 2009. 9:45.nVan Brabandt H, Neyt M. What is the evidence in favor of percutaneous aortic valve insertion? Am J Cardiol. 2009. 103(4):575.nDhruva SS, Bero LA, Redberg RF. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009. 302(24):2679-85.nSerruys PW, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009. 360(10):961-72.nRoques F, et al. Risk factors and outcome in European cardiac surgery: analysis of the EuroSCORE multinational database of 19030 patients. Eur J Cardiothorac Surg. 1999. 15(6):816-22; discussion 822-3.nShahian DM, et al. The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 3-valve plus coronary artery bypass grafting surgery. Ann Thorac Surg. 2009. 88(1 Suppl):S43-62.nJin R, Grunkemeier GL, Starr A. Validation and refinement of mortality risk models for heart valve surgery. Ann Thorac Surg. 2005. 80(2):471-9.nEdwards FH, et al. Prediction of operative mortality after valve replacement surgery. J Am Coll Cardiol. 2001. 37(3):885-92.nHannan EL, et al. Risk index for predicting in-hospital mortality for cardiac valve surgery. Ann Thorac Surg. 2007. 83(3):921-9.nGardner SC, et al. Comparison of short-term mortality risk factors for valve replacement versus coronary artery bypass graft surgery. Ann Thorac Surg. 2004. 77(2):549-56.nDewey TM, et al. Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 2008. 135(1):180-7.nNowicki ER, et al. Multivariable prediction of in-hospital mortality associated with aortic and mitral valve surgery in Northern New England. Ann Thorac Surg. 2004. 77(6):1966-77.nvan Gameren M, et al. Do we need separate risk stratification models for hospital mortality after heart valve surgery? Ann Thorac Surg. 2008. 85(3):921-30.nvan Gameren M, et al. How to assess risks of valve surgery: quality, implementation and future of risk models. Heart. 2009. 95(23):1958-63.nLee DH, et al. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation. 121(8):973-8.nGirardi LN, et al. No-clamp technique for valve repair or replacement in patients with a porcelain aorta. Ann Thorac Surg. 2005. 80(5):1688-92.nBaumgartner H, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr. 2009. 22(1):1-23; quiz 101-2.nRose C, Mandal AB. Int J Biolog Macromolecules. 1996;18:41-53.nMandal AB, Ramesh DV, Dhar SC. Eur J Biochem. 1987;169:617-628.nRose C, Kumar M, Mandal AB. Biochem J. 1988;249:127-133.nJudith R, Nithya M, Rose C, Mandal AB. Life Sci. 2010;87:1-8.nUsha R, Dhathathreyan A, Mandal AB, Ramasami T. J Appl. Poly Sci B. 2004;42:3859-3865.nUsha R, Jaimohan SM, Rajaram A, Mandal AB. Int J Biolog Macromolecules. 2010;47:402-409.nRamesh DV, Sehgal PK, Mandal AB, Dhar. SC. Leather Sci. 1986;33:88-90.nPushpakanth S, Balaji S, Sastry TP, Mandal AB. J Biomed Nanotech. 2008;4:62-66.nSastry TP, Sundaraseelan J, Swarnalatha K, Liji Sobhana SS, Umamaheswari M, Sekar S, Mandal AB. Nanotechnology. 2008;19:DoI, 245604.nSehgal PK, et al. Collagen bilayer dressing with Ciprofloxacin, an effective system for infected wound healing. J Biomater Sci Polymer Edn; 2007:18.nSehgal PK, et al. Improved collagen bilayer dressing for the controlled release of drugs. J Biomed Mater Res B Appl Biomater. 2004;70:389-396.nSehgal PK, et al. Fruit Extracts of Momordica charantia potentiate glucose uptake and up-regulate Glut-4, PPAR γ and PI-3K. Journal of Ethnopharmacology. 2009;126:533-539.nSehgal PK, et al. In vitro evaluation of antioxidants of fruit extract of Momordica charantia L. on fibroblasts and keratinocytes. Journal Of Agricultural and Food Chemistry. 2010;10:1518-1522.nSehgal PK, et al. Porous Keratin Scaffold - An effective biomaterial for tissue engineering and drug delivery. J Biomed Mater Res B Appl Biomater. 2010;92:5-12.nSystematic reductive annuloplasty of mitral and tricuspid valves in patients with end-stage ischemic dilated cardiomyopathy. Jonjev ZS, Mijatov M, Popovic S, Fabri M, Radovanovic N. J Card Surg 2007;22:111-116.nReductive annuloplasty of double orifices in patients with primary dilatative cardiomyopathy.nRadovanovic N, Mihajlovic B, Selestiansky J, Torbica V, Mijatov M, Popov M, Jonjev ZS. Ann Thorac Surg. 2002;73:751-5.nMitral valve surgery for chronic ischemic mitral regurgitation. Calafiore AM, Di Mauro M, Gallina S, Di Giammarco G, Iaco AL, Teodori G, Tavarozzi I. Ann Thorac Surg 2004;77(6):1989-1997.nNontransplant Surgical Options for Heart Failure. In: Edmunds HJrd, Cohn LH, editors. Cardiac Surgery in the Adult. Badhvar V, Bolling FS. 2003;1515-1526.nFundaro P, Pocar M, Moneta A, Donatelli F, Grossi A. Posterior mitral valve restoration for ischemic regurgitation. Ann Thorac Surg 2004;77(2):729-730.nLunde R, Sanders E, Hoskam JA. Right aortic arch symptomatic in adulthood. Neth J Med. 2002; 5:212-5.nApaydin M, Varer M, Sarsilmaz A, Akin H. Thyroid hemiagenesis. European Journal of Radiology Extra. 2007; 62:65-7nKleinert S, Sano T, Weintraub RG, Mee RB, Karl TR, Wilkinson JL. Anatomic features and surgical strategies in double-outlet right ventricle. Circulation. 997:19:1233-39.nJacobs JP, Franklin RC, Wilkinson JL, Cochrane AD, Karl TR, Aiello VD, Béland MJ, Colan SD, Elliott MJ, Gaynor JW, Krogmann ON, Kurosawa H, Maruszewski B, Stellin G, Tchervenkov CI, Weinberg PM. The nomenclature, definition and classification of discordant atrioventricular connections. Cardiol Young. 2006;16:72-84.nKarl TR, Weintraub RG, Brizard CP, Cochrane AD, Mee RB. Senning plus ASO for discordant (congenitally corrected) transposition. Ann Thorac Surg. 1997;64:495-502.nIsmat FA, Baldwin HS, Karl TR, Weinberg PM. Coronary anatomy in congenitally corrected transposition of the great arteries. Int J Cardiol. 2002;86(2-3):207-16.nWilkinson JL, Cochrane AD, Karl TR. Congenital Heart Surgery Nomenclature and Database Project: corrected (discordant) transposition of the great arteries (and related malformations). Ann Thorac Surg. 2000;69:S236-48.nSano T, Riesenfeld T, Karl TR, Wilkinson JL Intermediateterm outcome after intracardiac repair of associated cardiac defects in patients with atrioventricular and ventriculoarterial discordance. Circulation. 1995;92:II:272-8.nKarl, TR and Cochrane AD. Congenitally corrected transposition of the great arteries. In: Mavroudis C, Backer C. Pediatric Cardiac Surgery (Third Edition). St. Louis: Mosby, 2003; 476-495.n

Published

2010-11-10

How to Cite

Abstracts of 20th World CongressWorld Society of Cardio-Thoracic Surgeons - October 2010. (2010). The Heart Surgery Forum, 13, S2-S173. https://doi.org/10.1532/hsf.504

Issue

Section

Article